{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:41:41Z","timestamp":1774438901253,"version":"3.50.1"},"reference-count":27,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As part of the randomized MRC Myeloma IX trial, we compared an attenuated regimen of cyclophosphamide, thalidomide, and dexamethasone (CTDa; n = 426) with melphalan and prednisolone (MP; n = 423) in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation. The primary endpoints were overall response rate, progression-free survival, and overall survival (OS). The overall response rate was significantly higher with CTDa than MP (63.8% vs 32.6%; P &lt; .0001), primarily because of increases in the rate of complete responses (13.1% vs 2.4%) and very good partial responses (16.9% vs 1.7%). Progression-free survival and OS were similar between groups. In this population, OS correlated with the depth of response (P &lt; .0001) and favorable interphase fluorescence in situ hybridization profile (P &lt; .001). CTDa was associated with higher rates of thromboembolic events, constipation, infection, and neuropathy than MP. In elderly patients with newly diagnosed multiple myeloma (median age, 73 years), CTDa produced higher response rates than MP but was not associated with improved survival outcomes. We highlight the importance of cytogenetic profiling at diagnosis and effective management of adverse events. This trial was registered at International Standard Randomized Controlled Trials Number as #68454111.<\/jats:p>","DOI":"10.1182\/blood-2011-02-338665","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T00:30:35Z","timestamp":1307493035000},"page":"1231-1238","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":160,"title":["Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation"],"prefix":"10.1182","volume":"118","author":[{"given":"Gareth J.","family":"Morgan","sequence":"first","affiliation":[{"name":"Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter M.","family":"Gregory","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[{"name":"Nottingham University Hospital, Nottingham, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue E.","family":"Bell","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Szubert","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria Navarro","family":"Coy","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"St James's University Hospital, Leeds, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Feyler","sequence":"additional","affiliation":[{"name":"Calderdale and Huddersfield National Health Service (NHS) Trust, Huddersfield, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny L.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Nottingham University Hospital, Nottingham, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huw","family":"Roddie","sequence":"additional","affiliation":[{"name":"Western General Hospital, Edinburgh, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudius","family":"Rudin","sequence":"additional","affiliation":[{"name":"Royal Devon and Exeter Hospital, Exeter, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Drayson","sequence":"additional","affiliation":[{"name":"College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger G.","family":"Owen","sequence":"additional","affiliation":[{"name":"St James's University Hospital, Leeds, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona M.","family":"Ross","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham H.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Newcastle, Newcastle-upon-Tyne, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Anthony","family":"Child","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the NCRI Haematological Oncology Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"9","key":"2019111807413464100_B1","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111807413464100_B2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","article-title":"Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.","volume":"4","author":"Durie","year":"2003","journal-title":"Hematol J"},{"issue":"7","key":"2019111807413464100_B3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/10428190500085024","article-title":"The adverse prognostic impact of advanced age in multiple myeloma.","volume":"46","author":"Mileshkin","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111807413464100_B4","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.","volume":"16","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807413464100_B5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","article-title":"Treatment of multiple myeloma: a comprehensive review.","volume":"9","author":"Kyle","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"9","key":"2019111807413464100_B6","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2019111807413464100_B7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.leukres.2009.06.035","article-title":"Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.","volume":"34","author":"Holstein","year":"2010","journal-title":"Leuk Res"},{"issue":"3","key":"2019111807413464100_B8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111807413464100_B9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111807413464100_B10","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111807413464100_B11","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial.","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9594","key":"2019111807413464100_B12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"2019111807413464100_B13","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111807413464100_B14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111807413464100_B15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"19","key":"2019111807413464100_B16","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807413464100_B17","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428190600821955","article-title":"The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.","volume":"47","author":"Wu","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"9757","key":"2019111807413464100_B18","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"2019111807413464100_B19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.V116.21.623.623","article-title":"Thalidomide maintenance significantly improves progression-free survival (PFS) and overall survival (OS) of myeloma patients when effective relapse treatments are used: MRC Myeloma IX results [abstract].","volume":"116","author":"Morgan","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111807413464100_B20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111807413464100_B21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.1997.424","article-title":"Cautionary tales of survival analysis: conflicting analyses from a clinical trial in breast cancer.","volume":"76","author":"Gregory","year":"1997","journal-title":"Br J Cancer"},{"issue":"5","key":"2019111807413464100_B22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2008.07495.x","article-title":"Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.","volume":"144","author":"Offidani","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111807413464100_B23","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood-2008-02-140954","article-title":"First thalidomide clinical trial in multiple myeloma: a decade.","volume":"112","author":"van Rhee","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111807413464100_B24","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111807413464100_B25","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"2019111807413464100_B26","first-page":"235","article-title":"MP versus MPT for previously untreated elderly patients with multiple myeloma: a meta-analysis of survival of 1682 individual patient data from 6 randomized clinical trials [abstract].","volume":"95","author":"Waage","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"2019111807413464100_B27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis.","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/5\/1231\/1346868\/zh803111001231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/5\/1231\/1346868\/zh803111001231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:52:04Z","timestamp":1574063524000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/5\/1231\/28974\/Cyclophosphamide-thalidomide-and-dexamethasone-CTD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,4]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,8,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-338665","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,4]]}}}